Proposal:Cancer Drug Parity Act of 2021

This proposal is archived and closed to further debate. It was introduced in the 117th Congress, which has concluded, and the bill was not enacted into law.

Bill	HR 4385
Type of Legislation	House Bill
Congress	117
Status	Archived — 117th Congress concluded
Source	View original on Congress.gov

Geographic Scope

National

Description

Cancer Drug Parity Act of 2021

This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.

To comply with this requirement, plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

Bill Title

Cancer Drug Parity Act of 2021

Linked Goals

• Goal:Promote General Welfare

Steps

• 2021-07-09: Referred to the House Committee on Education and Labor.
• 2021-07-09: Introduced in House
• 2021-07-09: Introduced in House

Projected Outcome

A more informed proposal or public response aligned with the Promote General Welfare goal.